Navigation Links
Proteonomix, Inc. Announces Finalizing ECRF for Its Clinical Trial of UMK 121 in Patients with End Stage Liver Disease
Date:10/26/2012

PARAMUS, N.J., Oct. 26, 2012 /PRNewswire/ -- PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company and Numoda Corporation had finalized its Electronic Case Report Form for use in its clinical trial of UMK-121.

A case report form (or CRF) is a paper or electronic questionnaire (ECRF if electronic) used in clinical trial research. The ECRF is the tool used by the sponsor of a clinical trial to collect data from each participating site. All data on each patient participating in a clinical trial are held and/or documented in the ECRF, including adverse events.

The sponsor of the clinical trial, in this case Proteonomix, develops the CRF to collect the data needed to test their hypotheses or answer their research questions. The size of a CRF can be up to hundreds of pages of electronically captured data obtained over a period of weeks or months.

The sponsor or its designee is responsible for designing a CRF that accurately represents the protocol of the clinical trial, as well as managing its production, monitoring the data collection and auditing the content of the filled-in ECRFs. Case report forms contain data obtained during the patient's participation in the clinical trial. Before being sent to the sponsor, this data is usually de-identified (not traceable to the patient) by removing the patient's name, medical record number, etc., and giving the patient a unique study number. The supervising Institutional Review Board (IRB) oversees the release of any personally identifiable data to the sponsor.

From the sponsor's point of view, the main logistic goal of a clinical trial is to obtain accurate ECRFs. However, because of human and machine error, the data entered in ECRFs is rarely completely
'/>"/>

SOURCE Proteonomix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... subsidiary, BreedIT Ltd., the exclusive worldwide distributor of highly ... announced that on January 7, 2014, the Company,s board ... Ben-Zion Weiner as its new member of ... Weiner held executive positions with Teva Pharmaceutical Industries Ltd ...
(Date:1/15/2014)... -- MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ... than 10 bps, yet are surprisingly capable in their ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 /PRNewswire/ ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ... the market as insulin delivery systems especially ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... ANGELES, Sept. 30 Actresses and mother-daughter pair Blythe Danner ... Entertainment Industry Foundation (EIF) public service announcement that celebrates the ... of PSAs that all major broadcast networks - ABC, CBS, FOX ... EIF,s iParticipate national initiative to promote service ...
... 30 According to a new,market research report, ,Neurostimulation ... for,neurostimulation products is expected to be worth $3.6 billion ... driven by the multiple treatment,applications of neurostimulation products, and ... Browse 48 market data tables and ...
... Sept. 30 On Tuesday, September 22, 2009, ... largest co-payment assistance organizations, hosted a panel discussion to ... underinsured and the related challenges of reducing financial barriers ... ) , Held at the National Press Club ...
... , SUNNYVALE, Calif., Sept. 30 Palo Alto Networks(TM), the ... selected to present at the Computer Forensics Show 2009, taking ... Julie Starr, a distinguished engineer at Palo Alto Networks, will ... and Control" in the IT Security Track on Oct. 6. ...
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... (bupropion SR/zonisamide SR), the Company,s second late stage investigational ... primary efficacy endpoint by demonstrating statistically significantly greater weight ... placebo. The Company plans to meet with the ...
... CITY, Calif., Sept. 30 Genomic Health, Inc. ... Health,s Chief Operating Officer and Chief Financial Officer, will present ... City, on Tuesday, October 6 at 9:30 a.m. ET. ... the presentation, visit the Investor Relations section of Genomic Health,s ...
Cached Medicine News:Health News:Blythe Danner and Gwyneth Paltrow Ask Americans to Volunteer for Healthier Life in New Public Service Announcement 2Health News:Blythe Danner and Gwyneth Paltrow Ask Americans to Volunteer for Healthier Life in New Public Service Announcement 3Health News:MarketsandMarkets: Global Neurostimulation Market Worth US$10.2 Billion by 2014 2Health News:MarketsandMarkets: Global Neurostimulation Market Worth US$10.2 Billion by 2014 3Health News:HealthWell Foundation(R) Gathers Leading Health Care Stakeholders to Discuss Crisis of the Underinsured 2Health News:HealthWell Foundation(R) Gathers Leading Health Care Stakeholders to Discuss Crisis of the Underinsured 3Health News:Palo Alto Networks to Present at the Computer Forensics Show 2009 2Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 2Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 3Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 4Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 5Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 6
... Medtronic has been a key participant ... for more than a decade. Previous Medtronic ... for concentrated platelets, as well as to ... for producing platelet-rich plasma (PRP) for a ...
This unique hemostatic seal provides a simple option for beating heart CABG anastomoses, allowing you to use your own hand-suturing technique without the release of cerebral emboli associated with th...
... Biliary Self-Expanding Stent System combines low-profile, high radial ... .018" guide wire compatible stent system provides 6F ... diameters (5.0 - 10.0 mm). Now, with longer ... in five stent lengths (28, 38, 56, 80 ...
... Supreme and Response catheters comprise ... catheters available for electrophysiology procedures. Their ... provide for superior torque response with ... multiple curves and French sizes, Supreme ...
Medicine Products: